POINT Biopharma clinical trials
Acquired by Eli Lilly and Company, Dec 26, 2023 · source ↗
The registry lists 2 studies whose lead sponsor is POINT Biopharma. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 13, 2026.
- 2studies on the registry
- 0open to participants now
- 1phase 3 study under way
Before and after it joined Eli Lilly and Company
- First submitted before POINT Biopharma became part of Eli Lilly and Company
- 2
- First submitted after POINT Biopharma became part of Eli Lilly and Company
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs POINT Biopharma’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- Lutetium Lu 177 Zadavotide Guraxetan1 in phase 30 open · 1
All 2 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 121
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company2 studies
Something wrong with this grouping? Tell us on the Eli Lilly and Company page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All Eli Lilly and Company studies →
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentActive, not recruitingNCT04647526Phase 3
Sponsor listed in the registry: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company · First submitted before POINT Biopharma became part of Eli Lilly and Company
- FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)TerminatedNCT05432193Phase 1
Sponsor listed in the registry: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company · First submitted before POINT Biopharma became part of Eli Lilly and Company